Every few weeks we get a version of the same call. An operator has signed a supply agreement with a German importer, or has an investor asking about European channels. They have been told by a consultant, a booth vendor, or a competitor’s website that they need to “get EU-GMP certified.” They want to know how long the certification takes and what it costs.

The honest answer starts with a correction. EU-GMP certification is not something you buy, and no private company can sell it to you. It is issued by a European government authority after inspectors walk your building. Most of what they are looking at when they walk it is architecture.

That distinction changes what you should be doing right now. Here is the framework in the order an inspector will think about it.

What EU-GMP actually is

EU-GMP is the European Union’s Good Manufacturing Practice standard for medicinal products. It is published as EudraLex Volume 4, the rulebook every pharmaceutical manufacturer supplying the European market works under. Part I covers finished medicinal products. Part II covers active substances. A series of annexes addresses specific product types and topics.

Cannabis falls under EU-GMP because Germany and most other European markets treat medical cannabis as a medicine dispensed through pharmacies. That is the core point operators coming from state programs tend to miss. State cannabis regulation asks whether your facility is secure, tracked and safe to occupy. EU-GMP asks whether your facility can reliably produce a pharmaceutical product of consistent quality, batch after batch, and prove it with records.

For the building, the most important text is Chapter 3, Premises and Equipment. Its principle is short and demanding. Premises must be located, designed, constructed, adapted and maintained to suit the operations carried out in them. The layout must minimize the risk of errors and permit effective cleaning and maintenance to avoid cross-contamination and any adverse effect on product quality. Everything that follows in this post is a way of satisfying that sentence.

So who actually issues an EU-GMP certificate?

A European regulator. Nobody else.

An EU-GMP certificate is issued by the competent authority of a European Economic Area member state after an inspection of the site. The certificate is recorded in EudraGMDP, the European database that importers, pharmacies and other regulators use to confirm a site’s status. You can look any certified site up there, which is also how a buyer will check you.

Three separate things get collapsed into “EU-GMP certification,” and it helps to pull them apart:

1. The site passes a GMP inspection. Inspectors from an EEA competent authority audit the facility, its equipment, its quality system and its records. A site outside Europe is inspected by the authority of the member state its importer works with.

2. The product enters under a manufacturing or import authorisation. A European importer holds the authorisation to bring the product in. The importer’s Qualified Person, a named, legally accountable individual, certifies each batch before it can be released to market.

3. The market authority permits the product. In Germany, medical cannabis imports also require permits from BfArM, the federal medicines authority, alongside the GMP status of the supplying site.

Anyone selling you “EU-GMP certification” is selling preparation for step one. That preparation can be valuable. It is not the certificate, and a consultant cannot promise you the outcome of a government inspection.

One practical consequence: you cannot inspect your way out of a building problem. A quality system can be rewritten in weeks. A gowning sequence that crosses an unclassified corridor, or a waste route that shares a door with finished product, is a construction project. Inspectors know the difference, and they write findings accordingly.

Where GACP ends and GMP begins

Cannabis sits at an unusual seam in European pharmaceutical regulation, because it starts life as a plant.

Cultivation, harvest and initial handling fall under GACP, Good Agricultural and Collection Practice. The European Medicines Agency revised its GACP guideline as EMA/HMPC/246816/2005 Rev. 1, which took effect on August 12, 2025. The revision was updated in part to address indoor growing technologies, which makes it directly relevant to cannabis. From post-harvest processing onward, including drying for most operators supplying Germany, GMP takes over. Confirm the exact handover point for your product with your importer and quality partner.

Annex 7, Manufacture of Herbal Medicinal Products, is the annex that governs this transition. Most competitor pages skip it, and it is the one that matters most for plant-derived product.

In a building, that seam is a physical line. On one side is agricultural space: grow rooms, harvest, and the areas where plant material is handled as a crop. On the other side is pharmaceutical space: controlled drying, curing, trimming, packaging and storage, with gowning, defined air handling, cleanable finishes and documented material flow. The line needs a defined crossing point with an airlock, a change of environmental control, and a documented handover.

Drawing that line in the wrong place is one of the most common and most expensive errors we are called in to correct. Draw it too late and your drying rooms are running pharmaceutical operations in agricultural conditions. Draw it too early and you have paid for classified grow space you did not need.

The annexes that shape the building

Beyond Chapter 3 and Annex 7, four annexes do most of the work on a cannabis facility design.

Annex 1, Manufacture of Sterile Medicinal Products. Revised in 2022 and in force since August 25, 2023. Most cannabis products are not sterile, so Annex 1 is not mandatory for them. However, it is the reference text inspectors carry in their heads for cleanroom logic: Grade A through D classification, particle limits aligned with ISO 14644-1, airlock design, and the Contamination Control Strategy tying them together. Its guidance value of 10 to 15 Pascals between adjacent rooms of different grades is the working number most cannabis cascades are designed to. Designing to Annex 1 principles in non-sterile space is how you avoid arguing with an inspector about whether your approach is good enough.

Annex 15, Qualification and Validation. This is where design meets proof. Annex 15 requires that facilities and equipment be qualified through design qualification (DQ), installation qualification (IQ), operational qualification (OQ) and performance qualification (PQ). DQ is the one owners overlook. Your design documents are themselves qualified against your user requirements, which means drawings have to be organized so a validation team can test against them. A drawing set produced for a building permit is rarely structured that way.

Annex 11, Computerised Systems. Your building management system, environmental monitoring system and access control are computerised systems in GMP scope, because they generate the records proving your rooms held their conditions. A substantially revised Annex 11 and a new Annex 22, the first GMP guidance on artificial intelligence, went through public consultation that closed on October 7, 2025. Final versions were still pending at the time of writing. Design monitoring infrastructure now so that meeting the revised text later is a configuration exercise, not a demolition one.

Part I, Chapter 5, Production. Not an annex, but it drives layout. Its requirements for preventing cross-contamination and mix-ups are the reason material flow, segregation and dedicated areas show up on your floor plan rather than only in your procedures.

What the building has to do

Translate those texts into a floor plan and they reduce to a short list of things the building must physically accomplish.

Hold a classification plan. Every room gets a defined status, from unclassified to controlled-not-classified to graded space where open product is handled. For most non-sterile cannabis operations, that means Grade D principles or controlled-not-classified conditions for most rooms, with tighter control where product is exposed. Classification follows the process step, not a facility-wide grade. Be cautious of anyone who quotes you a single grade before seeing your process.

Move air in one direction. A pressure cascade keeps air flowing from cleaner spaces toward less clean ones, including when doors open. It only works if room volumes, door sizes, airlock hold volumes and air handling capacity are designed together. That is why it is set during architectural design, not handed to the mechanical contractor afterward.

Separate people from product, and product from waste. Gowning runs from street clothes to controlled space, room by room, with degowning on a separate route. Material flows from goods-in through quarantine, sampling, release, processing, packaging and dispatch in one direction. Waste and rejected material take a route that never crosses finished product. Where a constrained footprint forces flows to cross, the answer is time-based segregation and pass-throughs, with the rationale documented so it survives audit.

Be cleanable to the standard your SOPs claim. That means coved wall-to-floor junctions, smooth and sealed wall and ceiling systems, flush vision panels, resinous flooring, and every penetration sealed. Pinholes at conduit and pipe entries are a recurring audit finding, and they are invisible until someone looks.

Control drying as a pharmaceutical process. Dried flower has to meet pharmacopoeial quality specifications in Germany, including the German Pharmacopoeia (DAB) monograph for cannabis flowers and its microbial limits. Temperature, humidity and airflow in drying and curing rooms therefore become validated parameters, not preferences. Racking, surfaces and pest control in those rooms need to be designed for cleaning and inspection. Microbial performance is decided here more than anywhere else in the building.

Keep maintenance out of controlled space. Air handlers, filters, utilities and plant equipment should be serviceable without a technician gowning into a production room. Interstitial space and plant room location decide this, and both are set early.

Where EU-GMP collides with the fire code

If your facility includes solvent extraction, you are designing to two frameworks that want opposite things.

EU-GMP generally wants production rooms held positive to protect the product, often with recirculated, filtered air. A hydrocarbon extraction room must be held negative to keep a release contained, with once-through exhaust taken low to the floor. We cover the fire code side in detail in our guide to C1D1 extraction lab requirements.

Both can be satisfied, but not by accident. The usual resolution is an airlock arrangement that protects both directions at once. A pressurized “bubble” airlock keeps both the extraction room and the corridor from exchanging air directly. A depressurized “sink” airlock pulls from both sides. Choosing between them depends on what you are protecting most at that boundary. It is a design decision with fire, mechanical and quality consequences, and it is far cheaper to settle on paper than after the room is built.

New build or retrofit

Both paths reach the same standard. They are different problems.

A ground-up facility can be organized around flow from the first sketch. Controlled zones sit at the core, support and plant wrap around them, and floor-to-floor heights accommodate the interstitial space air handling actually needs. Costs are lower per square foot of controlled space, while pre-construction runs longer.

A retrofit is what most operators are facing: a licensed, working facility built to a state standard, and a new reason to reach EU-GMP. The work starts with a gap assessment against the target standard. It separates what can be fixed in place, what requires reconstruction, and what is a genuine constraint of the building. Common outcomes include inserting a gowning suite where there is no obvious room for one, rebalancing or replacing air handling to hold a cascade, and rerouting material flow around a doorway that cannot move. Phasing construction around licensed operations is usually the core of the job.

Retrofit is the harder problem and usually the more urgent one.

Germany: what the market actually requires

Germany is the reason most operators ask about EU-GMP. Since April 1, 2024, medical cannabis has been governed by the Medical Cannabis Act (MedCanG), outside the narcotics framework. The market is supplied largely through imports and dispensed through pharmacies.

For a supplying facility, the practical requirements are EU-GMP for manufacturing, GACP for cultivation, and product that meets German pharmacopoeial quality. Domestic manufacturing sites fall under the AMWHV, Germany’s manufacturing ordinance, and are inspected by the authority of the state (Land) where the facility sits. Inspection practice therefore varies regionally. Foreign sites are inspected by the EU authority associated with their importer.

The market is also not standing still. A MedCanG amendment approved by the German Federal Cabinet in October 2025 would require an in-person consultation before a first prescription and end mail-order dispensing. At the time of writing it had passed a first Bundestag reading but had not been enacted. It could change demand, but not the facility standard. EU-GMP applies either way.

If you are building for Germany, see our Germany cannabis facility design page for how we set up projects there, including metric drawings, coordination with German-registered planners, and European product standards.

Canada and the United States

Canadian producers start from Health Canada’s Good Production Practices under Part 5 of the Cannabis Regulations. GPP is a real baseline, but it is not EU-GMP. Producers exporting to Europe layer EU-GMP on top of it. The efficient decision is to design to EU-GMP from the start so the site is not rebuilt for a second audit. See our Canada cannabis facility design page for more.

US operators are in a moving situation. In April 2026, federal authorities moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III. A separate DEA proceeding on broader rescheduling concluded its hearing this summer and is awaiting a decision. None of that settles whether or how US-produced medical cannabis can be exported to Europe, so confirm the export question with regulatory counsel before investing on the strength of it.

What it does mean is that pharmaceutical-grade facility standards are becoming relevant to American operators faster than expected. A building organized to EU-GMP principles now keeps options open, whether the eventual target is Europe, US cGMP under 21 CFR Parts 210 and 211, or a buyer who simply wants proof of quality.

Design the building before you write the binder

Everything above reduces to one sequence. Confirm the target market and the standard it requires. Draw the GACP-to-GMP line. Build the classification plan, cascade and flows around the process. Then detail finishes and utilities, and document all of it so qualification protocols can be written directly against the drawings.

Operators who run that sequence in reverse write excellent SOPs for a building that cannot follow them. That is the most expensive way to fail an inspection, and it is avoidable.

Studio Bliss has designed facilities across more than 27 states, Canada and Germany, from 1,000 square foot tenant improvements to 100,000 square foot production plants. Our team brings licensed architects, interior designers and engineers under one roof. For EU-GMP work, we design the physical facility and coordinate directly with your quality lead, validation consultant and mechanical engineer. The result is drawings and a quality system that describe the same building.

We do not write quality systems, and we do not issue certifications. For the quality side of EU-GMP readiness, our friends at Cannaspire handle cannabis GMP certification prep.

If you are planning for European supply, or trying to work out whether your existing building can get there, explore our cannabis GMP facility design services or schedule a consultation. Bring us the building and the market, and we will tell you what it takes.